Topics

Durvalumab Regimens Improve PFS in Frontline Metastatic NSCLC

18:28 EDT 28 Oct 2019 | OncLive

The addition of durvalumab (Imfinzi) to platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy alone in patients with previously untreated metastatic non–small cell lung cancer.

Original Article: Durvalumab Regimens Improve PFS in Frontline Metastatic NSCLC

NEXT ARTICLE

More From BioPortfolio on "Durvalumab Regimens Improve PFS in Frontline Metastatic NSCLC"

Quick Search

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...